Tara Franks, Chief Operating Officer of TD2, receives 2024 Phoenix Titan 100 Award

July 3, 2024

Titan CEO and headline sponsor Wipfli LLP are pleased to announce Tara Franks, MBA, Chief Operating Officer of Translational Drug Development (TD2) as a 2024 Phoenix Titan 100. The Titan 100 program recognizes Phoenix’s Top 100 CEOs & C-level executives. They are the area’s most accomplished business leaders in their industry using criteria that include demonstrating exceptional leadership, vision, and passion. Collectively the 2024 Phoenix Titan 100 and their companies employ over 105,000 individuals and generate over $34 billion in annual revenues. This year’s honorees will be published in a limited-edition Titan 100 book and profiled exclusively online. They will be honored at an awards ceremony on September 26th, 2024, and will be given the opportunity to interact and connect multiple times throughout the year with their fellow Titans.

“The Titan 100 are changing the way that business is done in Phoenix. These preeminent leaders have built a distinguished reputation that is unrivaled and preeminent in their field. We proudly recognize the Titan 100 for their efforts to shape the future of the Phoenix business community. Their achievements create a profound impact that makes an extraordinary difference for their employees and clients across the nation.” says Jaime Zawmon, President of Titan CEO.

"Ms. Franks has continued to demonstrate exceptional leadership and strategic acumen in driving TD2's growth and success within the oncology drug development industry through 2024. Her profound insight and innovative approach have further solidified TD2's position as a major player in critical areas such as pancreatic cancer, cell therapy, and glioblastoma. With her expertise, she has consistently outperformed market growth rates and spearheaded operational improvements, directed the integration of new capabilities and is leading our global expansion,” said Dr. Stephen Gately, President and CEO of TD2. “Tara remains widely acknowledged as a respected industry leader, sought after for her valuable insights by biotech start-ups and oncology companies."

Tara Franks will be honored at the Titan 100 awards on September 26th, 2024, at the Chateau Luxe. Set amongst spectacular Sonoran Desert views, Chateau Luxe is Arizona’s most luxurious and nationally recognized event destination. This unique cocktail-style awards event will gather 100 Titans of Industry and their guests for an evening unlike anything that exists in the Phoenix business community.

“On behalf of all the partners and associates at Wipfli we congratulate all the Titan100 winners. It’s an honor to recognize this diverse group of leaders in the Phoenix community. We appreciate the lasting impact each leader has made, and continues to make, in building organizations of significance both here in Arizona and abroad. Your ingenuity and creativity have set you apart, and the honor of being seen as an industry Titan is richly deserved,” says Ryan Lindsay, partner at Wipfli.

Top Trends in ADC Drug Development

Antibody drug conjugates (ADCs) represent a significant advancement in cancer therapy, combining monoclonal antibodies with potent chemotherapeutic ...

Read more +

Unlocking Insights: Top 5 Reasons to Incorporate Orthotopic GBM PDX Models into Your Preclinical Evaluation

In the landscape of glioblastoma multiforme (GBM) research, the utilization of Orthotopic GBM Patient-Derived Xenograft (PDX) models stands as a ...

Read more +

The Vital Role of Highly Characterized Glioblastoma PDX Models in Preclinical Cancer Research: Insights from TD2's Most Recent Studies

The fight against Glioblastoma multiforme (GBM), one of the most aggressive forms of brain cancer, hinges on the development and use of advanced ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.